Clinical Trials Directory

Trials / Completed

CompletedNCT02004548

Phase I Clinical Study of Metatinib Tromethamine Tablet

A Phase I, Multiple Dose Escalation Clinical Trial of Metatinib Tromethamine Tablet in Patients With Advanced or Metastatic Solid Tumors

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
18 (actual)
Sponsor
Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
Sex
All
Age
18 Years – 74 Years
Healthy volunteers
Not accepted

Summary

Primary Objective: To evaluate the safety, tolerability and maximum tolerated dose (MTD) of daily oral administration of metatinib tromethamine in subjects with solid tumors; Investigate the influence of food on pharmacokinetic parameters. Secondary Objective: To evaluate the plasma pharmacokinetics (PK) of daily oral administration of metatinib tromethamine in subjects with solid tumors; To observe preliminary anti-tumor efficacy; To evaluate potential pharmacodynamic and predictive biomarkers at MTD.

Conditions

Interventions

TypeNameDescription
DRUGMetatinib Tromethamine

Timeline

Start date
2013-05-01
Primary completion
2015-09-01
Completion
2015-12-01
First posted
2013-12-09
Last updated
2015-12-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT02004548. Inclusion in this directory is not an endorsement.